Shares of Grifols have moved 12.4% today, and are now trading at a price of $8.2. In contrast, the S&P 500 index saw a 1.1% change and the Dow Industrial Average posted a 1.9% performance. Today's trading volume is 2,131,964 compared to the stock's average volume of 1,359,420.
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. Based in Barcelona, the company has 27,584 full time employees and a market cap of $6,727,078,912.
The company is now trading -29.96% away from its average analyst target price of $11.7 per share. The 2 analysts following the stock have set target prices ranging from $10.4 to $13.01, and on average give Grifols a rating of hold.
Over the last year, GRFS shares have gone down by -39.1%, which represents a difference of -23.6% when compared to the S&P 500. The stock's 52 week high is $13.34 per share and its 52 week low is $5.71. With its gross margins declining an average -4.4% over the last four years, Grifols may not have a strong enough business to reverse this trend.
If you would like a free fundamental analysis of Grifols and other stocks that interest you, subscribe to our free newsletter!